A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration

[1]  R. Spaide Choroidal Neovascularization , 2020, Pathologic Myopia.

[2]  Malcolm Kohler,et al.  A prospective evaluation , 2016 .

[3]  G. Ying,et al.  Size and Growth of Geographic Atrophy During 5 Years of Follow Up in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) , 2016 .

[4]  Christian Simader,et al.  Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD. , 2016, Ophthalmology.

[5]  I. Mantel,et al.  Factors Influencing the Treatment Response of Pigment Epithelium Detachment in Age-Related Macular Degeneration. , 2015, American journal of ophthalmology.

[6]  S. Byeon,et al.  Association between choroidal thickness and the response to intravitreal ranibizumab injection in age‐related macular degeneration , 2015, Acta ophthalmologica.

[7]  Glenn J Jaffe,et al.  Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. , 2015, Ophthalmology.

[8]  R. Spaide,et al.  MULTIMODAL IMAGING FINDINGS AND MULTIMODAL VISION TESTING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2015, Retina.

[9]  P. Campochiaro,et al.  Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab. , 2015, Ophthalmology.

[10]  C. Curcio,et al.  OUTER RETINAL TUBULATION IN ADVANCED AGE-RELATED MACULAR DEGENERATION: Optical Coherence Tomographic Findings Correspond to Histology , 2015, Retina.

[11]  Georg Langs,et al.  Spatio-Temporal Signatures to Predict Retinal Disease Recurrence , 2015, IPMI.

[12]  Georg Langs,et al.  Predicting Semantic Descriptions from Medical Images with Convolutional Neural Networks , 2015, IPMI.

[13]  Z. Haskova,et al.  Baseline predictors of early visual acuity improvement in RVO patients treated with ranibizumab in the SHORE study , 2015 .

[14]  I. Mantel,et al.  REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome , 2015, Retina.

[15]  Christoph K. Hitzenberger,et al.  Progression of Retinal Pigment Epithelial Atrophy in Antiangiogenic Therapy of Neovascular Age-Related Macular Degeneration , 2015, American journal of ophthalmology.

[16]  I. Mantel,et al.  INCIDENCE OF OUTER RETINAL TUBULATION IN RANIBIZUMAB-TREATED AGE-RELATED MACULAR DEGENERATION , 2015, Retina.

[17]  G. Ying,et al.  Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. , 2015, Ophthalmology.

[18]  R. Fimmers,et al.  Scotopic and Photopic Microperimetry in Patients With Reticular Drusen and Age-Related Macular Degeneration. , 2015, JAMA ophthalmology.

[19]  C. Curcio,et al.  Clinicopathological correlation of outer retinal tubulation in age-related macular degeneration. , 2015, JAMA ophthalmology.

[20]  E. Stone Genetic testing for age-related macular degeneration: not indicated now. , 2015, JAMA ophthalmology.

[21]  Christian Simader,et al.  Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. , 2015, Ophthalmology.

[22]  Sina Farsiu,et al.  Relationship of central choroidal thickness with age-related macular degeneration status. , 2015, American journal of ophthalmology.

[23]  Jesse J. Jung,et al.  TYPE 3 NEOVASCULARIZATION: Evolution, Association With Pigment Epithelial Detachment, and Treatment Response as Revealed by Spectral Domain Optical Coherence Tomography , 2015, Retina.

[24]  C. Curcio,et al.  Inner Segment Remodeling and Mitochondrial Translocation in Cone Photoreceptors in Age-Related Macular Degeneration With Outer Retinal Tubulation. , 2015, Investigative ophthalmology & visual science.

[25]  K. Freund,et al.  En face OCT angiography demonstrates flow in early type 3 neovascularization (retinal angiomatous proliferation) , 2015, Eye.

[26]  Milan Sonka,et al.  Stratified Sampling Voxel Classification for Segmentation of Intraretinal and Subretinal Fluid in Longitudinal Clinical OCT Data , 2015, IEEE Transactions on Medical Imaging.

[27]  Kang Zhang,et al.  PHARMACOGENOMICS OF RESPONSE TO ANTI-VEGF THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2015, Retina.

[28]  Edwin M. Stone,et al.  Complement activation and choriocapillaris loss in early AMD: Implications for pathophysiology and therapy , 2015, Progress in Retinal and Eye Research.

[29]  H. Kawashima,et al.  Effects of posterior vitreous detachment on aqueous humour levels of VEGF and inflammatory cytokines , 2015, British Journal of Ophthalmology.

[30]  Y. Modi,et al.  Comparative Safety and Tolerability of Anti-VEGF Therapy in Age-Related Macular Degeneration , 2015, Drug Safety.

[31]  Jiayan Huang,et al.  Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). , 2015, Ophthalmology.

[32]  H. Kim,et al.  Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. , 2015, American journal of ophthalmology.

[33]  C. Ramsay,et al.  Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review. , 2015, Ophthalmology.

[34]  A. Schachat,et al.  Optical coherence tomography, fluorescein angiography, and the management of neovascular age-related macular degeneration. , 2015, Ophthalmology.

[35]  M. Tolentino,et al.  Drugs in Phase II clinical trials for the treatment of age-related macular degeneration , 2015, Expert opinion on investigational drugs.

[36]  Christian Simader,et al.  Quantitative comparison of macular segmentation performance using identical retinal regions across multiple spectral-domain optical coherence tomography instruments , 2015, British Journal of Ophthalmology.

[37]  Jesse J. Jung,et al.  GEOGRAPHIC ATROPHY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2014, Retina.

[38]  P. Campochiaro,et al.  Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. , 2015, American journal of ophthalmology.

[39]  G. Ying,et al.  Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.

[40]  Terje R Pedersen,et al.  Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. , 2015, Ophthalmology.

[41]  A. Ho,et al.  Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. , 2015, American journal of ophthalmology.

[42]  G. Ying,et al.  Outer retinal tubulation in the comparison of age-related macular degeneration treatments trials (CATT). , 2014, Ophthalmology.

[43]  Lauren N Ayton,et al.  Optical coherence tomography-defined changes preceding the development of drusen-associated atrophy in age-related macular degeneration. , 2014, Ophthalmology.

[44]  Richard F Spaide,et al.  Visualization of the posterior vitreous with dynamic focusing and windowed averaging swept source optical coherence tomography. , 2014, American journal of ophthalmology.

[45]  Eric M. Moult,et al.  Ultrahigh-speed swept-source OCT angiography in exudative AMD. , 2014, Ophthalmic surgery, lasers & imaging retina.

[46]  Robert Tibshirani,et al.  Quantitative SD-OCT imaging biomarkers as indicators of age-related macular degeneration progression. , 2014, Investigative ophthalmology & visual science.

[47]  Ursula Schmidt-Erfurth,et al.  A quantitative approach to identify morphological features relevant for visual function in ranibizumab therapy of neovascular AMD. , 2014, Investigative ophthalmology & visual science.

[48]  K. Freund,et al.  THE PEARL NECKLACE SIGN: A Novel Spectral Domain Optical Coherence Tomography Finding in Exudative Macular Disease , 2014, Retina.

[49]  Jesse J. Jung,et al.  The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. , 2014, American journal of ophthalmology.

[50]  Georg Langs,et al.  Motion Artefact Correction in Retinal Optical Coherence Tomography Using Local Symmetry , 2014, MICCAI.

[51]  Giovanni Staurenghi,et al.  Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration , 2014, British Journal of Ophthalmology.

[52]  Georg Langs,et al.  Stable registration of pathological 3D-OCT scans using retinal vessels , 2014 .

[53]  Giovanni Staurenghi,et al.  Clinical characteristics of reticular pseudodrusen in the fellow eye of patients with unilateral neovascular age-related macular degeneration. , 2014, Ophthalmology.

[54]  Francesco Bandello,et al.  Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA) , 2014, British Journal of Ophthalmology.

[55]  Glenn J Jaffe,et al.  Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. , 2014, JAMA ophthalmology.

[56]  U. Schmidt-Erfurth,et al.  Impact of vitreomacular adhesion on ranibizumab mono- and combination therapy for neovascular age-related macular degeneration. , 2014, American journal of ophthalmology.

[57]  Myeong Jin Ju,et al.  Simultaneous investigation of vascular and retinal pigment epithelial pathologies of exudative macular diseases by multifunctional optical coherence tomography. , 2014, Investigative ophthalmology & visual science.

[58]  R. Guymer,et al.  ANTI-VEGF TREATMENT IN NEOVASCULAR AGE–RELATED MACULAR DEGENERATION: A Treat-and-Extend Protocol Over 2 Years , 2014, Retina.

[59]  S. Sadda,et al.  Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the IN•OCT consensus. , 2014, Ophthalmology.

[60]  Christian Simader,et al.  Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy , 2014, British Journal of Ophthalmology.

[61]  Wolfgang Drexler,et al.  Choroid, Haller's, and Sattler's layer thickness in intermediate age-related macular degeneration with and without fellow neovascular eyes. , 2014, Investigative ophthalmology & visual science.

[62]  S. Sadda,et al.  Effect of Anti-VEGF Treatment on Choroidal Thickness over Time in Patients with Neovascular Age-related Macular Degeneration , 2014, European journal of ophthalmology.

[63]  M. Larsen,et al.  MULTILAYERED PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2014, Retina.

[64]  A. Merkur,et al.  EXACERBATION OF CHOROIDAL AND RETINAL PIGMENT EPITHELIAL ATROPHY AFTER ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2014, Retina.

[65]  K. Freund,et al.  SUBRETINAL HYPERREFLECTIVE EXUDATION ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2014, Retina.

[66]  E. Rahimy,et al.  Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis). , 2014, Transactions of the American Ophthalmological Society.

[67]  Christian Simader,et al.  Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. , 2014, Ophthalmology.

[68]  Jiayan Huang,et al.  VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). , 2014, JAMA ophthalmology.

[69]  U Chakravarthy,et al.  The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. , 2014, Ophthalmology.

[70]  M. Sonka,et al.  Quantifying disrupted outer retinal-subretinal layer in SD-OCT images in choroidal neovascularization. , 2014, Investigative ophthalmology & visual science.

[71]  Jiayan Huang,et al.  Risk of scar in the comparison of age-related macular degeneration treatments trials. , 2014, Ophthalmology.

[72]  Martin F. Kraus,et al.  Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration. , 2014, Ophthalmology.

[73]  Amitha Domalpally,et al.  Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. , 2014, Ophthalmology.

[74]  Michael Pircher,et al.  Adaptive optics SLO/OCT for 3D imaging of human photoreceptors in vivo. , 2014, Biomedical optics express.

[75]  Chun-Fang Xu,et al.  GENETIC FACTORS ASSOCIATED WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB IN KOREAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2014, Retina.

[76]  Richard F Spaide,et al.  Assessing the cone photoreceptor mosaic in eyes with pseudodrusen and soft Drusen in vivo using adaptive optics imaging. , 2014, Ophthalmology.

[77]  Alauddin Bhuiyan,et al.  Progress on retinal image analysis for age related macular degeneration , 2014, Progress in Retinal and Eye Research.

[78]  Hyuncheol Kim,et al.  Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. , 2014, Investigative Ophthalmology and Visual Science.

[79]  Leopold Schmetterer,et al.  Doppler Optical Coherence Tomography , 2014, Progress in Retinal and Eye Research.

[80]  H. Flynn,et al.  Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. , 2013, Ophthalmic surgery, lasers & imaging retina.

[81]  Glenn J Jaffe,et al.  Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.

[82]  E. Stone,et al.  Is age-related macular degeneration a microvascular disease? , 2014, Advances in experimental medicine and biology.

[83]  R. Guymer,et al.  Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. , 2014, Survey of ophthalmology.

[84]  Glenn J Jaffe,et al.  Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. , 2014, Ophthalmology.

[85]  Milan Sonka,et al.  Relationships of retinal structure and humphrey 24-2 visual field thresholds in patients with glaucoma. , 2014, Investigative ophthalmology & visual science.

[86]  Gerhard Goos,et al.  Medical Image Computing and Computer-Assisted Intervention – MICCAI 2014 , 2014, Lecture Notes in Computer Science.

[87]  U. Schmidt-Erfurth,et al.  Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. , 2013, Ophthalmology.

[88]  Susanne Binder,et al.  The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. , 2013, Ophthalmology.

[89]  S. Harding,et al.  Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study. , 2013, Ophthalmology.

[90]  Pearse A Keane,et al.  Optical coherence tomography-based observation of the natural history of drusenoid lesion in eyes with dry age-related macular degeneration. , 2013, Ophthalmology.

[91]  A. Roorda,et al.  Cone structure imaged with adaptive optics scanning laser ophthalmoscopy in eyes with nonneovascular age-related macular degeneration. , 2013, Investigative ophthalmology & visual science.

[92]  M. Larsen,et al.  Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography. , 2013, American journal of ophthalmology.

[93]  David R Williams,et al.  In vivo imaging of retinal pigment epithelium cells in age related macular degeneration. , 2013, Biomedical optics express.

[94]  Usha Chakravarthy,et al.  Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial , 2013, The Lancet.

[95]  P. Keane,et al.  Relationship between Visual Acuity and Spectral Domain Optical Coherence Tomography Retinal Parameters in Neovascular Age-Related Macular Degeneration , 2013, Ophthalmologica.

[96]  S. Kishi,et al.  Evolution of vitreomacular detachment in healthy subjects. , 2013, JAMA ophthalmology.

[97]  Glenn J Jaffe,et al.  Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. , 2013, Ophthalmology.

[98]  E. Rahimy,et al.  PROSPECTIVE EVALUATION OF THE INCIDENCE AND RISK FACTORS FOR THE DEVELOPMENT OF RPE TEARS AFTER HIGH- AND LOW-DOSE RANIBIZUMAB THERAPY , 2013, Retina.

[99]  Richard F Spaide,et al.  Optical coherence tomography: imaging of the choroid and beyond. , 2013, Survey of ophthalmology.

[100]  R. Guymer,et al.  Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. , 2013, Ophthalmology.

[101]  M. Larsen,et al.  Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab. , 2013, American journal of ophthalmology.

[102]  W. Freeman,et al.  CORRELATION OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY CHARACTERISTICS WITH VISUAL ACUITY IN EYES WITH SUBFOVEAL SCARRING AFTER TREATMENT FOR WET AGE-RELATED MACULAR DEGENERATION , 2013, Retina.

[103]  M. Knopp,et al.  ANATOMIC AND PHARMACOKINETIC PROPERTIES OF INTRAVITREAL BEVACIZUMAB AND RANIBIZUMAB AFTER VITRECTOMY AND LENSECTOMY , 2013, Retina.

[104]  Allen C Ho,et al.  Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2013, Ophthalmology.

[105]  Sina Farsiu,et al.  Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. , 2013, Ophthalmology.

[106]  S. Sivaprasad,et al.  Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab. , 2013, American journal of ophthalmology.

[107]  Usha Chakravarthy,et al.  Clinical classification of age-related macular degeneration. , 2013, Ophthalmology.

[108]  F. Falcão-Reis,et al.  Characterization of Neovascular Age-Related Macular Degeneration Patients with Outer Retinal Tubulations , 2013, Ophthalmologica.

[109]  Gerard Mimoun,et al.  CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE: The LUMIERE Study , 2013, Retina.

[110]  William J Feuer,et al.  QUANTITATIVE CHANGES IN RETINAL PIGMENT EPITHELIAL DETACHMENTS AS A PREDICTOR FOR RETREATMENT WITH ANTI-VEGF THERAPY , 2013, Retina.

[111]  E. Souied,et al.  MULTIMODAL EVALUATION OF FOVEAL SPARING IN PATIENTS WITH GEOGRAPHICATROPHY DUE TO AGE-RELATED MACULAR DEGENERATION , 2013, Retina.

[112]  P. Rosenfeld,et al.  Increasing volume of a retinal pigmented epithelial detachment as a predictor of submacular hemorrhage during anti-VEGF therapy. , 2013, Ophthalmic surgery, lasers & imaging retina.

[113]  Ivana K. Kim,et al.  Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). , 2013, Ophthalmology.

[114]  H. Hoerauf,et al.  Posterior vitreous detachment following intravitreal drug injection , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.

[115]  R. Spaide,et al.  Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration. , 2013, Ophthalmology.

[116]  M. Larsen,et al.  Predictors of 1‐year visual outcome in neovascular age‐related macular degeneration following intravitreal ranibizumab treatment , 2013, Acta ophthalmologica.

[117]  Correlation of OCT characteristics and retinal sensitivity in neovascular age-related macular degeneration in the course of monthly ranibizumab treatment. , 2013, Investigative ophthalmology & visual science.

[118]  Glenn J Jaffe,et al.  Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. , 2013, Ophthalmology.

[119]  E. Makalic,et al.  Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. , 2013, Ophthalmology.

[120]  Jost B Jonas,et al.  Subfoveal choroidal thickness: the Beijing Eye Study. , 2013, Ophthalmology.

[121]  M. Mandai,et al.  Recovery of photoreceptor outer segments after anti-VEGF therapy for age-related macular degeneration , 2013, Graefe's Archive for Clinical and Experimental Ophthalmology.

[122]  Milan Sonka,et al.  Quantification of external limiting membrane disruption caused by diabetic macular edema from SD-OCT. , 2012, Investigative ophthalmology & visual science.

[123]  Judy E. Kim,et al.  Ocular Hypertension Following Intravitreal Anti-vascular Endothelial Growth Factor Agents , 2012, Drugs & Aging.

[124]  M. Sonka,et al.  Automated segmentation of the choroid from clinical SD-OCT. , 2012, Investigative ophthalmology & visual science.

[125]  B. J. Klevering,et al.  Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. , 2012, Ophthalmology.

[126]  U. Schmidt-Erfurth,et al.  Correlation of SD-OCT features and retinal sensitivity in neovascular age-related macular degeneration. , 2012, Investigative ophthalmology & visual science.

[127]  F. Roudot-thoraval,et al.  Hyperreflective Dots: A New Spectral-Domain Optical Coherence Tomography Entity for Follow-Up and Prognosis in Exudative Age-Related Macular Degeneration , 2012, Ophthalmologica.

[128]  Adnan Tufail,et al.  Evaluation of age-related macular degeneration with optical coherence tomography. , 2012, Survey of ophthalmology.

[129]  I. Bhutto,et al.  Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. , 2012, Molecular aspects of medicine.

[130]  Hideki Koizumi,et al.  Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. , 2012, Ophthalmology.

[131]  J. Kim,et al.  Improvement of photoreceptor integrity and associated visual outcome in neovascular age-related macular degeneration. , 2012, American journal of ophthalmology.

[132]  Stefanie G. Schuman,et al.  Spatial correlation between hyperpigmentary changes on color fundus photography and hyperreflective foci on SDOCT in intermediate AMD. , 2012, Investigative ophthalmology & visual science.

[133]  Noemi Lois,et al.  Progression of retinal pigment epithelial atrophy in stargardt disease. , 2012, American journal of ophthalmology.

[134]  Usha Chakravarthy,et al.  Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. , 2012, Ophthalmology.

[135]  G. Ying,et al.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.

[136]  Harald Sattmann,et al.  Polarization sensitive optical coherence tomography of melanin provides intrinsic contrast based on depolarization , 2012, Biomedical optics express.

[137]  N. Bressler,et al.  Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. , 2012, Archives of ophthalmology.

[138]  A. Tsujikawa,et al.  Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization , 2012, Clinical ophthalmology.

[139]  N. Hawkes Avastin is as effective as Lucentis for wet AMD and could save NHS £84m a year, study shows , 2012, BMJ : British Medical Journal.

[140]  U. Schmidt-Erfurth,et al.  Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. , 2012, Ophthalmology.

[141]  P. Kaiser,et al.  Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. , 2012, Ophthalmology.

[142]  M. Neudorfer,et al.  Differential optical density of subretinal spaces. , 2012, Investigative ophthalmology & visual science.

[143]  R. Guymer,et al.  Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. , 2012, American journal of ophthalmology.

[144]  William J Feuer,et al.  Quantitative imaging of retinal pigment epithelial detachments using spectral-domain optical coherence tomography. , 2012, American journal of ophthalmology.

[145]  D. Jaafar,et al.  Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study. , 2012, American journal of ophthalmology.

[146]  E. Souied,et al.  LONGITUDINAL ANATOMICAL RESPONSE OF RETINAL–CHOROIDAL ANASTOMOSIS TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY , 2012, Retina.

[147]  U. Schmidt-Erfurth,et al.  INFLUENCE OF VITREOMACULAR ADHESION ON THE DEVELOPMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION: 4-Year Results of a Longitudinal Study , 2012, Retina.

[148]  S. Boyd,et al.  Effectiveness at 1 Year of Monthly versus Variable-Dosing Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-related Macular Degeneration , 2012, Retina.

[149]  P. Patel,et al.  OPTIMIZING INDIVIDUALIZED THERAPY WITH BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. , 2012, Retina.

[150]  A. Tsujikawa,et al.  Relationship between retinal morphological findings and visual function in age-related macular degeneration , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[151]  Bernhard Baumann,et al.  Reproducibility of choroidal thickness measurements across three spectral domain optical coherence tomography systems. , 2011, Ophthalmology.

[152]  R. Molday,et al.  Progress in Retinal and Eye Research , 2012 .

[153]  L. Hjelmqvist,et al.  One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study , 2011, Journal of ophthalmology.

[154]  E. Lenassi,et al.  Efficacy of 12‐month treatment of neovascular age‐related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections , 2011, Acta ophthalmologica.

[155]  U. Schmidt-Erfurth,et al.  Polarization sensitive optical coherence tomography in the human eye , 2011, Progress in Retinal and Eye Research.

[156]  C. Curcio,et al.  ANATOMICAL CORRELATES TO THE BANDS SEEN IN THE OUTER RETINA BY OPTICAL COHERENCE TOMOGRAPHY: Literature Review and Model , 2011, Retina.

[157]  Hyewon Chung,et al.  ASSOCIATION BETWEEN FOVEAL MICROSTRUCTURE AND VISUAL OUTCOME IN AGE-RELATED MACULAR DEGENERATION , 2011, Retina.

[158]  Srinivas R Sadda,et al.  Spatial distribution of posterior pole choroidal thickness by spectral domain optical coherence tomography. , 2011, Investigative ophthalmology & visual science.

[159]  Joan W. Miller,et al.  Spectral-domain optical coherence tomography as an indicator of fluorescein angiography leakage from choroidal neovascularization. , 2011, Investigative ophthalmology & visual science.

[160]  E. Souied,et al.  Cystoid macular degeneration in exudative age-related macular degeneration. , 2011, American journal of ophthalmology.

[161]  C. Masuet-Aumatell,et al.  ONE-YEAR RESULTS OF A FLEXIBLE REGIMEN WITH RANIBIZUMAB THERAPY IN MACULAR DEGENERATION: Relationship with the Number of Injections , 2011, Retina.

[162]  Masahiro Akiba,et al.  Macular choroidal thickness and volume in normal subjects measured by swept-source optical coherence tomography. , 2011, Investigative ophthalmology & visual science.

[163]  R. Guymer,et al.  Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD. , 2011, Investigative ophthalmology & visual science.

[164]  J. Townend,et al.  GEOGRAPHIC ATROPHY IN RETINAL ANGIOMATOUS PROLIFERATION , 2011, Retina.

[165]  Christian Ahlers,et al.  Performance of automated drusen detection by polarization-sensitive optical coherence tomography. , 2011, Investigative ophthalmology & visual science.

[166]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[167]  Ivana K. Kim,et al.  Genetics of Age-Related Macular Degeneration: Current Concepts, Future Directions , 2011, Seminars in ophthalmology.

[168]  U. Schmidt-Erfurth,et al.  Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. , 2011, Ophthalmology.

[169]  Joan W. Miller,et al.  DISPLAYED REFLECTIVITY OF CHOROIDAL NEOVASCULAR MEMBRANES BY OPTICAL COHERENCE TOMOGRAPHY CORRELATES WITH PRESENCE of LEAKAGE BY FLUORESCEIN ANGIOGRAPHY , 2011, Retina.

[170]  William J Feuer,et al.  Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography. , 2011, Ophthalmology.

[171]  R. Guymer,et al.  Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. , 2011, Ophthalmology.

[172]  Shuichi Makita,et al.  Three-dimensional visualization of ocular vascular pathology by optical coherence angiography in vivo. , 2011, Investigative ophthalmology & visual science.

[173]  Dominic McHugh,et al.  Optical coherence tomography may be used to predict visual acuity in patients with macular edema. , 2011, Investigative ophthalmology & visual science.

[174]  H. Gerding,et al.  Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome , 2011, Graefe's Archive for Clinical and Experimental Ophthalmology.

[175]  S. Mennel,et al.  Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections , 2011, Acta ophthalmologica.

[176]  D. Pauleikhoff,et al.  [Anti-VEGF therapy of exudative AMD: Prognostic factors for therapy success]. , 2011, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

[177]  Susanne Binder,et al.  Spectral domain optical coherence tomography for higher precision in the evaluation of vitreoretinal adhesions in exudative age-related macular degeneration , 2011, British Journal of Ophthalmology.

[178]  Christian Simader,et al.  A systematic comparison of spectral-domain optical coherence tomography and fundus autofluorescence in patients with geographic atrophy. , 2011, Ophthalmology.

[179]  R. Kawasaki,et al.  Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[180]  H. Koh,et al.  Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. , 2011, Ophthalmology.

[181]  S. Sadda,et al.  Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[182]  P. Mitchell,et al.  Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis , 2010, BMC ophthalmology.

[183]  P. Charbel Issa,et al.  The significance of the complement system for the pathogenesis of age-related macular degeneration — current evidence and translation into clinical application , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[184]  K. Eng,et al.  Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review. , 2010, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[185]  H. Koh,et al.  Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration , 2010, Japanese Journal of Ophthalmology.

[186]  P. Keane,et al.  Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration. , 2010, Investigative ophthalmology & visual science.

[187]  C. Regillo,et al.  A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. , 2010, Ophthalmology.

[188]  S. Harding,et al.  Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy , 2010, British Journal of Ophthalmology.

[189]  K Bailey Freund,et al.  Do We Need a New Classification for Choroidal Neovascularization in Age-Related Macular Degeneration? , 2010, Retina.

[190]  G. Quentel,et al.  Retinal pseudocysts in age-related geographic atrophy. , 2010, American journal of ophthalmology.

[191]  Masayuki Hata,et al.  The significance of external limiting membrane status for visual acuity in age-related macular degeneration. , 2010, American journal of ophthalmology.

[192]  D. Pauleikhoff,et al.  Anti-VEGF-Therapie der exsudativen AMD , 2010, Der Ophthalmologe.

[193]  Christian Ahlers,et al.  Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomography. , 2010, Investigative ophthalmology & visual science.

[194]  Don H. Anderson,et al.  The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited , 2010, Progress in Retinal and Eye Research.

[195]  U. Schmidt-Erfurth,et al.  Effect of intravitreal bevacizumab (Avastin®) in neovascular age‐related macular degeneration using a treatment regimen based on optical coherence tomography: 6‐ and 12‐month results , 2009, Acta ophthalmologica.

[196]  Laura A. Hecker,et al.  Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. , 2010, Human molecular genetics.

[197]  K Bailey Freund,et al.  Outer retinal tubulation: a novel optical coherence tomography finding. , 2009, Archives of ophthalmology.

[198]  U. Schmidt-Erfurth,et al.  Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. , 2009, Ophthalmology.

[199]  B. Rosner,et al.  Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. , 2009, Investigative ophthalmology & visual science.

[200]  P. Keane,et al.  Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation , 2009, British Journal of Ophthalmology.

[201]  Takayuki Baba,et al.  Relationship between RPE and choriocapillaris in age-related macular degeneration. , 2009, Investigative ophthalmology & visual science.

[202]  G. Quentel,et al.  Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. , 2009, American journal of ophthalmology.

[203]  U. Schmidt-Erfurth,et al.  Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration , 2009, British Journal of Ophthalmology.

[204]  J. Xu,et al.  What determines the switch between atrophic and neovascular forms of age related macular degeneration? - the role of BMP4 induced senescence , 2009, Aging.

[205]  Christian Ahlers,et al.  Identification of optical density ratios in subretinal fluid as a clinically relevant biomarker in exudative macular disease. , 2009, Investigative ophthalmology & visual science.

[206]  Srinivas R Sadda,et al.  Quantitative subanalysis of cystoid spaces and outer nuclear layer using optical coherence tomography in age-related macular degeneration. , 2009, Investigative ophthalmology & visual science.

[207]  A. Tsujikawa,et al.  Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration. , 2009, American journal of ophthalmology.

[208]  Joel S Schuman,et al.  Assessment of artifacts and reproducibility across spectral- and time-domain optical coherence tomography devices. , 2009, Ophthalmology.

[209]  Matthias Bolz,et al.  Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. , 2009, Ophthalmology.

[210]  Xiaodong Wu,et al.  Automated 3-D Intraretinal Layer Segmentation of Macular Spectral-Domain Optical Coherence Tomography Images , 2009, IEEE Transactions on Medical Imaging.

[211]  Susanne Binder,et al.  Quality of the threshold algorithm in age-related macular degeneration: Stratus versus Cirrus OCT. , 2009, Investigative ophthalmology & visual science.

[212]  Ronald Klein,et al.  Risk of advanced age-related macular degeneration after cataract surgery in the Age-Related Eye Disease Study: AREDS report 25. , 2009, Ophthalmology.

[213]  Philip J Rosenfeld,et al.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.

[214]  이성준 Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration : paired eye study , 2009 .

[215]  P. Keane,et al.  Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration. , 2008, Ophthalmology.

[216]  Paul G. Updike,et al.  Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration. , 2008, Investigative ophthalmology & visual science.

[217]  D. Sarraf,et al.  PREDICTORS OF Anti-VEGF-ASSOCIATED RETINAL PIGMENT EPITHELIAL TEAR USING FA AND OCT ANALYSIS , 2008, Retina.

[218]  S. Mennel,et al.  Vitreomacular traction and exudative age‐related macular degeneration , 2008, Acta ophthalmologica.

[219]  Martin Oppermann,et al.  Systemic Complement Activation in Age-Related Macular Degeneration , 2008, PloS one.

[220]  M. Trese,et al.  Posterior Vitreous Detachment Alters Retinal Penetration of Intravitreal Bevacizumab (Avastin) in Rabbit Eyes , 2008 .

[221]  Xiaodong Wu,et al.  Intraretinal Layer Segmentation of Macular Optical Coherence Tomography Images Using Optimal 3-D Graph Search , 2008, IEEE Transactions on Medical Imaging.

[222]  A. Bird,et al.  FUNDUS AUTOFLUORESCENCE IMAGING: Review and Perspectives , 2008, Retina.

[223]  U Chakravarthy,et al.  Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation , 2008, British Journal of Ophthalmology.

[224]  C. Regillo,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.

[225]  V. Arshavsky,et al.  Progress in Retinal and Eye Research , 2008 .

[226]  P. Kaiser,et al.  Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. , 2007, American journal of ophthalmology.

[227]  W. Brannath,et al.  Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? , 2007, American journal of ophthalmology.

[228]  L. Jampol,et al.  Optical coherence tomography use in evaluation of the vitreoretinal interface: a review. , 2007, Survey of ophthalmology.

[229]  D. Sarraf,et al.  TEARS OF THE RETINAL PIGMENT EPITHELIUM: An Old Problem in a New Era , 2007, Retina.

[230]  Jens Dreyhaupt,et al.  Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. , 2007, American journal of ophthalmology.

[231]  R. Bhisitkul,et al.  Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. , 2007, Ophthalmology.

[232]  William J Feuer,et al.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.

[233]  Edwin M Stone,et al.  Macular degeneration. , 2007, Annual review of medicine.

[234]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[235]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[236]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[237]  Richard F Spaide,et al.  INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION , 2006, Retina.

[238]  L. Labree,et al.  Errors in retinal thickness measurements obtained by optical coherence tomography. , 2006, Ophthalmology.

[239]  A. Ramé [Age-related macular degeneration]. , 2006, Revue de l'infirmiere.

[240]  Ronald Klein,et al.  A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. , 2005, Archives of ophthalmology.

[241]  G. Staurenghi,et al.  The Fellow Eye in Retinal Angiomatous Proliferation (RAP) , 2005 .

[242]  Leslie Hyman,et al.  A Simplified Severity Scale for Age-Related Macular Degeneration , 2005 .

[243]  J. Sebag Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[244]  Marco A Zarbin,et al.  Current concepts in the pathogenesis of age-related macular degeneration. , 2004, Archives of ophthalmology.

[245]  Neil M Bressler,et al.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. , 2002, American journal of ophthalmology.

[246]  Robert F. Mullins,et al.  An Integrated Hypothesis That Considers Drusen as Biomarkers of Immune-Mediated Processes at the RPE-Bruch's Membrane Interface in Aging and Age-Related Macular Degeneration , 2001, Progress in Retinal and Eye Research.

[247]  N. Bressler,et al.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.

[248]  C. Curcio,et al.  The Alabama Age-Related Macular Degeneration Grading System for donor eyes. , 1998, Investigative ophthalmology & visual science.

[249]  G. Ripandelli,et al.  Optical coherence tomography. , 1998, Seminars in ophthalmology.

[250]  C K Dorey,et al.  In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. , 1995, Investigative ophthalmology & visual science.

[251]  E Reichel,et al.  Quantitative assessment of macular edema with optical coherence tomography. , 1995, Archives of ophthalmology.

[252]  A. Fercher,et al.  In vivo optical coherence tomography. , 1993, American journal of ophthalmology.

[253]  Age-related macular degeneration. The Macular Photocoagulation Study. , 1984, American journal of ophthalmology.

[254]  P. Henkind Stereoscopic Atlas of Macular Diseases , 1971 .